Literature DB >> 7462536

Prednisolone disposition in steroid-dependent asthmatic children.

J Q Rose, J A Nickelsen, E F Ellis, E Middleton, W J Jusko.   

Abstract

The pharmacokinetics of a 40-mg intravenous dose of prednisolone were determined in 10 steroid-dependent asthmatic children with highly variable prednisone requirements (5 mg every other day to 40 mg a day). Concentrations of prednisolone and cortisol in plasma over a 24-hr test period were measured by high-performance liquid chromatography. Eosinophil concentrations and the concentration-dependent protein binding of prednisolone were also determined. The mean (+/-SD) apparent half-life of prednisolone in these children was 2.5 +/- 0.5 hr. The mean total volume of distribution was 52.8 +/- 14.5 L/1.73 m2 and mean plasma clearance was 246 +/- 62 ml/min/1.73 m2. These pharmacokinetic parameters, as well as the protein binding and eosinopenic response, were similar to values from healthy and steroid-dependent asthmatic adults. The data were also similar in both responsive and relatively resistant patients. The pharmacokinetics and protein binding of prednisolone are not responsible for the highly variable prednisone requirement and clinical response of these children to prednisone therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7462536     DOI: 10.1016/0091-6749(81)90060-9

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

Review 1.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  Evidence for different subgroups of difficult asthma in children.

Authors:  D N Payne; N M Wilson; A James; H Hablas; C Agrafioti; A Bush
Journal:  Thorax       Date:  2001-05       Impact factor: 9.139

3.  Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study.

Authors:  Anna Carmela P Sagcal-Gironella; Catherine M T Sherwin; Rommel G Tirona; Michael J Rieder; Hermine I Brunner; Alexander A Vinks
Journal:  Clin Ther       Date:  2011-10-07       Impact factor: 3.393

4.  Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia.

Authors:  I Choonara; J Wheeldon; P Rayner; M Blackburn; I Lewis
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Disposition of pulse dose methylprednisolone in adult and paediatric patients with the nephrotic syndrome.

Authors:  B M Assael; G Banfi; A C Appiani; A Edefonti; W J Jusko
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

Review 7.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

8.  Effect of inflammatory bowel disease on absorption and disposition of prednisolone.

Authors:  R L Milsap; D E George; S J Szefler; K A Murray; E Lebenthal; W J Jusko
Journal:  Dig Dis Sci       Date:  1983-02       Impact factor: 3.199

Review 9.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

10.  Pharmacokinetics of prednisolone in children: an open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease.

Authors:  Sissel Sundell Haslund-Krog; Maria Schmidt; Ron Mathot; Andreas Kryger Jensen; Inger Merete Jørgensen; Helle Holst
Journal:  BMJ Paediatr Open       Date:  2019-09-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.